Dr. Kimberly J. Henderson, MD, JD, Assistant
Medical Professor of emergency medicine at the Ichan School of
Medicine at Mount Sinai, and Dr. Joshua H.
Atkins, MD, PhD, Associate Professor of Anesthesiology and
Critical Care at the Hospital of the University of Pennsylvania, to join the SHL
Telemedicine US Advisory Board
TEL
AVIV, Israel and ZURICH, July 27,
2022 /PRNewswire/ -- SHL Telemedicine Ltd. (SIX
Swiss Exchange: SHLTN) ("SHL"), a leading provider and developer of
advanced personal telemedicine solutions, announced today the
appointment of new key opinion leaders (KOLs) as members to its US
Advisory Board, as part of its strategy to significantly expand the
use of SmartHeart® technology in the US.
Dr. Kimberly J. Henderson, MD, JD, has over 17 years
of experience in the medical field. Dr. Henderson is an Assistant Medical Professor of
emergency medicine at the Ichan School of Medicine at Mount Sinai.
She is the managing director and the Associate Medical Director at
a multinational investment management and financial services
company, where she provides direct oversight and coordination among
the firm's global medical, health, and wellness services. Prior to
that, Dr. Henderson was the Senior
Medical Director at CVS Health, where she spent 14 years supporting
enterprise-wide initiatives and retail health programs, including
oversight of MinuteClinic nurse practitioners. Dr. Henderson holds a JD and MD from Georgetown University.
Dr. Joshua H. Atkins, MD, PhD is
an academic anesthesiologist with more than 17 years of diverse
experience at Penn Medicine, one of the top 3 research medical
schools in the US. Dr. Atkins is engaged in clinical research that
focuses on respiratory monitoring, physiology of sleep apnea and
patient safety. He is a consultant to major companies such as
Medtronic and Beckton Dickinson (BD)
and has extensive experience in advocacy with regulatory and
legislative groups.
"We are pleased to have attracted these key opinion leaders to
join our US Advisory Board," said Erez Nachtomy, CEO of SHL
Telemedicine. "We are confident they will play a valuable role in
providing our US team with insight and guidance to support our
strategy for fast growth in the US market."
About SHL Telemedicine
SHL Telemedicine is engaged in developing and marketing personal
telemedicine systems and the provision of medical call center
services, with a focus on cardiovascular and related diseases, to
end users and to the healthcare community. SHL Telemedicine offers
its services and personal telemedicine devices to subscribers
utilizing telephonic and Internet communication technology. SHL is
listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885,
Security No.: 1128957). For more information, please visit our web
site at www.shl-telemedicine.com.
Some of the information contained in this press release contains
forward-looking statements. Readers are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results
may differ materially from those in the forward-looking statements
as a result of various factors. SHL Telemedicine undertakes no
obligation to publicly update or revise any forward-looking
statements.
Logo - https://mma.prnewswire.com/media/1850421/SHL_Logo.jpg
Further information:
Fabienne Farner
IRF
+41 43 244 81 42
farner@irf-reputation.ch
View original
content:https://www.prnewswire.com/news-releases/shl-telemedicine-bolsters-its-us-advisory-board-as-the-growth-of-its-smartheart-solution-accelerates-301594094.html
SOURCE SHL Telemedicine Ltd.